8-K: Sensus Healthcare Reports Strong Second Quarter 2024 Results, Revenue More Than Doubles

Sensus Healthcare's second quarter 2024 revenue more than doubled compared to the same period last year, reaching $9.2 million, with adjusted EBITDA also turning positive.

Summary

• Sensus Healthcare announced its financial results for the second quarter of 2024, showing significant growth.
• Revenues for the quarter reached $9.2 million, a 104% increase compared to $4.5 million in the second quarter of 2023.
• The company shipped 23 systems in the quarter, including three to Asia, compared to 13 systems in the same quarter last year.
• Net income for the quarter was $1.6 million, or $0.10 per diluted share, a significant improvement from a net loss of $0.4 million, or $0.02 per share, in the prior year.
• Adjusted EBITDA was $2.1 million, compared to a negative $1.0 million in the second quarter of 2023.
• The company's Fair Deal Agreement program has gained traction, with 15 agreements signed since its launch in March.
• Cash and cash equivalents stood at $19.0 million at the end of the quarter, with no debt.
• Accounts receivable increased to $18.3 million from $10.6 million at the end of 2023.
• For the first half of 2024, revenues were $20.0 million, a 152% increase compared to $8.0 million in the first half of 2023.
• Net income for the first half of 2024 was $3.9 million, or $0.24 per diluted share, compared to a net loss of $2.3 million, or $0.14 per share, for the first half of 2023.
• Adjusted EBITDA for the first half of 2024 was $5.1 million, compared to negative $3.7 million for the first half of 2023.

Sentiment

Score: 9

Explanation: The document conveys a very positive sentiment due to the significant revenue growth, return to profitability, and successful launch of the Fair Deal Agreement program. The company's strong financial performance and positive outlook suggest a high level of confidence.

Positives

• The company experienced substantial revenue growth in both the second quarter and the first half of 2024.
• Sensus Healthcare achieved profitability in the second quarter, turning around from a loss in the same period last year.
• The Fair Deal Agreement program is gaining momentum and is expected to contribute to future recurring revenue.
• International sales efforts, particularly in Asia, are progressing well.
• The company has a strong cash position with $19.0 million in cash and no debt.
• Gross profit margins improved to 58.7% in Q2 2024 compared to 57.9% in Q2 2023.
• Selling and marketing expenses decreased year-over-year, contributing to improved profitability.

Negatives

• Accounts receivable increased significantly to $18.3 million, which could indicate potential issues with collecting payments.
• General and administrative expenses increased due to higher professional fees and compensation.
• Cash and cash equivalents decreased from $23.1 million at the end of 2023 to $19.0 million as of June 30, 2024.

Risks

• The company's ability to maintain profitability is dependent on continued sales growth.
• Inflationary pressures could impact sales and profitability.
• Changes in government or third-party payor reimbursement for procedures using their products could affect sales.
• The company faces risks associated with doing business in China and other foreign countries.
• A concentration of sales to one particular customer in the U.S. poses a risk.
• The company's ability to protect its intellectual property is crucial for its continued success.

Future Outlook

The company expects to generate recurring revenue from the Fair Deal Agreement program in 2025 and anticipates continued growth from the utilization of SRT for treating non-melanoma skin cancer and keloids. They also aim to establish distribution in South Korea and Japan.

Management Comments

• Our sales momentum continued in the second quarter of 2024 with very strong revenue growth over the 2023 second quarter, along with positive net income and positive Adjusted EBITDA, said Joe Sardano, Chairman and Chief Executive Officer of Sensus Healthcare.
• Our Fair Deal Agreement is off to a strong start with 15 agreements signed since our launch at the American Academy of Dermatology meeting in March.
• We expect to be generating recurring revenue from these SRT-100 Vision (IG-SRT) systems in 2025.
• Given the growing utilization of SRT to treat non-melanoma skin cancer and keloids, and the interest we have generated to date, we expect this model to contribute to our growth for years to come.
• Our goal is to make SRT the standard of care for treating non-melanoma skin cancer and keloids, and we are energized by this tremendous global opportunity.

Industry Context

The announcement reflects a positive trend in the medical device industry, particularly in the area of non-invasive cancer treatments. The company's focus on superficial radiotherapy aligns with the growing demand for less invasive and more patient-centric treatment options. The expansion into Asia also reflects a broader trend of medical device companies seeking growth in international markets.

Comparison to Industry Standards

• Sensus Healthcare's revenue growth of 104% in Q2 2024 and 152% in H1 2024 significantly outperforms many established medical device companies, which typically see single-digit or low double-digit growth.
• Companies like Accuray Incorporated (ARAY) and Varian Medical Systems (VAR) are competitors in the radiation oncology space, but they focus on more complex and expensive treatments. Sensus's focus on superficial radiotherapy for skin conditions provides a niche market.
• The positive adjusted EBITDA of $2.1 million in Q2 2024 and $5.1 million in H1 2024 is a significant improvement compared to the previous year and indicates a strong turnaround in profitability.
• The Fair Deal Agreement program is a unique approach that could provide a competitive advantage by addressing customer capital constraints, unlike traditional sales models used by competitors.

Stakeholder Impact

• Shareholders will likely react positively to the strong financial results and positive outlook.
• Employees may benefit from the company's growth and improved financial stability.
• Customers will have access to innovative and effective treatment options.
• Suppliers may see increased demand for their products and services.
• Creditors will have increased confidence in the company's ability to meet its obligations.

Next Steps

• The company will continue to focus on expanding its Fair Deal Agreement program.
• Sensus Healthcare will work to establish distribution in South Korea and Japan.
• The company will continue to build inventory to meet anticipated customer demand.
• Management will host a conference call to discuss the financial results and provide a business update.

Key Dates

Keywords

Sensus Healthcare, Superficial Radiotherapy, SRT, IG-SRT, Skin Cancer, Keloids, Medical Devices, Financial Results, Revenue Growth, EBITDA, Fair Deal Agreement, Non-GAAP